Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cognition Therapeutics Inc (CGTX)

Cognition Therapeutics Inc (CGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

CGTX : 0.4400 (unch)
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

CGTX : 0.4400 (unch)
November’s Small-Cap Treasures: 3 Stocks Poised for Growth

Three promising small-cap stocks, poised for growth in healthcare, cybersecurity, and renewable energy, offer compelling investment opportunities for November.

LODE : 0.3425 (-1.44%)
CGTX : 0.4400 (unch)
ASNS : 1.1900 (unch)
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

CGTX : 0.4400 (unch)
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

CGTX : 0.4400 (unch)
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD

CGTX : 0.4400 (unch)
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

CGTX : 0.4400 (unch)
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Ongoing Patient Dosing in SHIMMER Study for DLB and SHINE Study for Alzheimer’s DiseasePositive Preliminary Data for Dry AMD Program Presented at ARVO...

CGTX : 0.4400 (unch)
Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer’s Disease Processes

Presented at Alzheimer’s Association International Conference August 4, 2022...

CGTX : 0.4400 (unch)
Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer’s Disease

 - Analyses Demonstrate CT1812 Impact on Alzheimer’s Disease Processes - NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc....

CGTX : 0.4400 (unch)

Barchart Exclusives

1 AI Stock to Buy and Hold for Long-Term Growth
Pure Storage stands out in AI data storage, bolstered by a new partnership with CoreWeave and a solid financial track record, making it an intriguing stock for AI-focused investors Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar